Bicocca Open Archive

Logo unimib boa
GERUSSI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.720
EU - Europa 7.434
AS - Asia 6.619
SA - Sud America 992
Continente sconosciuto - Info sul continente non disponibili 560
AF - Africa 175
OC - Oceania 8
Totale 27.508
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.097
SE - Svezia 2.390
SG - Singapore 2.139
IT - Italia 2.083
VN - Vietnam 1.419
CN - Cina 1.101
HK - Hong Kong 880
RU - Federazione Russa 735
BR - Brasile 728
DE - Germania 702
CA - Canada 400
IE - Irlanda 346
GB - Regno Unito 304
FR - Francia 211
IN - India 205
BD - Bangladesh 166
KR - Corea 130
FI - Finlandia 113
ID - Indonesia 103
AR - Argentina 99
NL - Olanda 96
ES - Italia 69
IQ - Iraq 68
AT - Austria 66
ZA - Sudafrica 65
PL - Polonia 62
TR - Turchia 57
CH - Svizzera 56
MX - Messico 55
SA - Arabia Saudita 47
PH - Filippine 42
UA - Ucraina 41
EC - Ecuador 40
MY - Malesia 40
CO - Colombia 34
PK - Pakistan 34
JP - Giappone 31
CR - Costa Rica 29
VE - Venezuela 29
DK - Danimarca 28
JM - Giamaica 28
BE - Belgio 26
UZ - Uzbekistan 25
LT - Lituania 24
TT - Trinidad e Tobago 24
IL - Israele 21
MA - Marocco 20
SV - El Salvador 16
CL - Cile 15
GT - Guatemala 15
KE - Kenya 15
CZ - Repubblica Ceca 14
TN - Tunisia 14
PY - Paraguay 13
AZ - Azerbaigian 12
BO - Bolivia 12
EG - Egitto 12
JO - Giordania 12
AE - Emirati Arabi Uniti 10
ET - Etiopia 10
HN - Honduras 10
IR - Iran 10
KZ - Kazakistan 10
NI - Nicaragua 10
DZ - Algeria 9
SK - Slovacchia (Repubblica Slovacca) 9
UY - Uruguay 9
AU - Australia 7
GR - Grecia 7
PE - Perù 7
PR - Porto Rico 7
PT - Portogallo 7
RS - Serbia 7
TW - Taiwan 7
NP - Nepal 6
PA - Panama 6
HU - Ungheria 5
MM - Myanmar 5
RO - Romania 5
SY - Repubblica araba siriana 5
AO - Angola 4
CI - Costa d'Avorio 4
CW - ???statistics.table.value.countryCode.CW??? 4
DO - Repubblica Dominicana 4
GP - Guadalupe 4
MD - Moldavia 4
PS - Palestinian Territory 4
QA - Qatar 4
TH - Thailandia 4
AG - Antigua e Barbuda 3
AL - Albania 3
BG - Bulgaria 3
CG - Congo 3
EE - Estonia 3
GE - Georgia 3
GY - Guiana 3
KG - Kirghizistan 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
Totale 26.895
Salva come PNG Salva come JPEG
Città #
Stockholm 1.882
Ashburn 1.315
Singapore 1.293
Ann Arbor 1.272
San Jose 871
Hong Kong 848
Milan 730
Frankfurt am Main 522
Ho Chi Minh City 432
Council Bluffs 401
Hanoi 362
Fairfield 361
Dublin 329
Dallas 310
Chandler 293
Los Angeles 285
Chicago 275
Wilmington 271
Toronto 267
New York 266
Santa Clara 256
Hefei 221
Boardman 183
Woodbridge 168
Rome 159
Seattle 156
The Dalles 153
Houston 151
Beijing 132
Seoul 124
London 120
Cambridge 119
Princeton 105
Columbus 102
Lauterbourg 102
Buffalo 88
Jakarta 78
Shanghai 75
São Paulo 75
Helsinki 74
Moscow 70
Dearborn 66
Munich 62
Phoenix 61
Turin 55
Orem 53
Zurich 48
Altamura 46
Lawrence 46
Montreal 43
Warsaw 43
Da Nang 41
Haiphong 41
Monza 39
Denver 38
Atlanta 37
Biên Hòa 35
Florence 35
Brooklyn 34
Johannesburg 34
Naples 33
San Diego 33
Vienna 31
Ha Long 30
Figino 29
Nuremberg 29
Rio de Janeiro 29
Charlotte 28
Tokyo 27
Hải Dương 26
Jacksonville 26
North Bergen 26
Pune 25
Washington 25
Boston 24
Bologna 23
Can Tho 23
Quận Bình Thạnh 23
Baghdad 22
New Delhi 22
Salt Lake City 22
San José 22
Turku 22
Amsterdam 21
Brussels 21
Mumbai 21
Ninh Bình 21
San Francisco 21
Guangzhou 20
Riyadh 20
Tashkent 20
Chennai 19
Bari 18
Belo Horizonte 18
Lappeenranta 17
Tampa 17
Bắc Ninh 16
Cagliari 16
Genoa 16
Jeddah 16
Totale 17.071
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 2.032
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 645
Gamma-Glutamyl Transferase in Patients With Primary Biliary Cholangitis 474
Mapping the human genetic architecture of COVID-19 464
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 448
A second update on mapping the human genetic architecture of COVID-19 441
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 387
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 383
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 374
Risk stratification in primary sclerosing cholangitis 369
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 367
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 366
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 365
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 359
Precision medicine in primary biliary cholangitis 355
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 345
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 340
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 332
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 325
New Therapeutic Targets in Autoimmune Cholangiopathies 324
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 321
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 318
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 312
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 310
Artificial Intelligence and liver: Opportunities and barriers 308
Better end points needed in primary sclerosing cholangitis trials 298
DISSECTING THE GENETIC ARCHITECTURE OF AUTOIMMUNITY: A SPOTLIGHT ON PRIMARY BILIARY CHOLANGITIS 297
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 293
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 291
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 286
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 284
Artificial intelligence for precision medicine in autoimmune liver disease 284
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 273
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 272
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 272
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 272
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 271
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score 270
Steroid-loaded Avidin-Nucleic-Acid-Nano-Assemblies reduce hepatic fibrosis modulating Kupffer cells in primary biliary cholangitis 262
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 261
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 260
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study 259
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 258
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 258
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 255
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 254
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 254
X marks the spot in autoimmunity 247
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 247
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 244
The phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants 243
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 242
The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities 241
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 237
Established cirrhosis at the time of diagnosis predicts adverse outcome in autoimmune hepatitis: A retrospective cohort study 235
The immunobiology of female predominance in primary biliary cholangitis 232
Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis 232
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis 232
Diagnostic Yield of Whole Exome Sequencing in Adult-onset Cholestatic Liver Disease 231
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 225
New insights on the role of human leukocyte antigen complex in primary biliary cholangitis 217
Open challenges in the management of autoimmune hepatitis 216
The Role of Epigenetics in Primary Biliary Cholangitis 214
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 211
Automating liver biopsy segmentation with a robust, open-source tool for pathology research: the HOTSPoT model 208
Cost of illness of Primary Biliary Cholangitis - a population-based study 208
Bacterascites confers poor patient prognosis beyond MELD prediction 204
LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis 204
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group 195
The application of artificial intelligence in hepatology: A systematic review 190
Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis 183
Gender differences in liver disease and the drug-dose gender gap 182
Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 181
MEDTEC students against coronavirus: Investigating the role of hemostatic genes in the predisposition to COVID-19 severity 179
GWAS and autoimmunity: What have we learned and what next 176
The role of ethnicity in autoimmune hepatitis 176
EFFICACY OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS-AUTOIMMUNE HEPATITIS OVERLAP PATIENTS WITH PERSISTENTLY ELEVATED TRANSAMINASES DESPITE IMMUNOSUPPRESSION 170
Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All 166
The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis 163
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis 162
Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy 161
Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase 155
Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase 155
Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 147
Elevated baseline igg is a risk factor for on-treatment flares of autoimmune hepatitis in patients in biochemical remission 146
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis 141
Kupffer cell autophagy emerges as a central regulator of immune dysregulation in primary biliary cholangitis 138
Primary Sclerosing Cholangitis 138
Diagnosing Autoimmune Hepatitis: Histological Correlations and Emerging Technologies 136
ANTITUMOR ACTIVITY OF A NOVEL FGFR INHIBITOR IN INTRAHEPATIC CHOLANGIOCARCINOMA 135
Genetics of Primary Biliary Cholangitis 132
Genetics of Autoimmune Liver Diseases 132
Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know 125
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis 124
Cluster analysis reveals the prognostic role of serum albumin within the normal range in patients with primary biliary cholangitis 122
Radiomics-Based Prognostication in Primary Sclerosing Cholangitis: A Proof-of-Concept Study 121
Black Ethnicity Affects the Clinical Presentation and Outcome in Autoimmune Hepatitis 121
The genetic architecture of primary biliary cholangitis 118
Editorial: liver transplantation for primary biliary cholangitis–the need for timely and more effective treatments 111
Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis 106
Totale 26.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.729
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.729
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022680 0 0 0 108 79 61 43 69 48 25 85 162
2022/20231.850 172 440 148 141 236 245 86 90 112 64 70 46
2023/20241.644 49 59 75 161 187 328 207 37 76 172 40 253
2024/20253.885 254 400 218 187 325 197 247 209 426 532 361 529
2025/202612.635 1.536 827 807 1.113 954 499 1.422 519 797 2.715 590 856
2026/20273.751 406 566 1.247 1.532 0 0 0 0 0 0 0 0
Totale 27.508